Tools for AD Research: Design of BACE2 Ligands
AD 研究工具:BACE2 配体的设计
基本信息
- 批准号:7021009
- 负责人:
- 金额:$ 21.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-01 至 2008-06-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs diseaseamyloid proteinsaspartic endopeptidasesbioassaybrain disorder chemotherapycell free systemchemical bindingchemical kineticschemical registry /resourcecombinatorial chemistrycomputational biologycomputer simulationcytotoxicitydrug discovery /isolationenzyme inhibitorsisozymesligandsnanotechnologysmall molecule
项目摘要
DESCRIPTION (provided by applicant): This R21 exploratory proposal uses an integrated, target-oriented approach in the rational development of BACE2 inhibitors - chemical tools that can be used to explore the basic biology of BACE2 and improve the selectivity of presently discovered active BACE1 inhibitors that are currently being developed as medications for Alzheimer's disease. There exists a broad consensus in the AD research community that the key to successful treatment of AD lies in the specific inhibition of BACE1. BACE1 is crucial for release of the amyloidogenic fragments that later form the extracellular neuritic amyloid plaques - one of factors in the pathogenesis of AD. Most of the known BACE1 inhibitors are relatively non-selective and target other aspartic proteases including the highly homologous BACE2. It has been shown that BACE2 may serve as an alternative alpha-secretase, another crucial enzyme that plays an important role in degradation of the amyloid precursor protein (APR), inhibition of which is highly undesirable. To better understand the role of BACE2 in human physiology and APP processing, we believe that selective inhibitors of this enzyme are needed as research tools. We hypothesize that it should be possible to design and synthesize inhibitors for BACE2 using an integrated multidisciplinary approach based on the combination of the computer-aided drug design, medicinal chemistry, and biology. Those compounds demonstrating BACE2 activity in the low nanomolar range will be screened at the whole cell level for their ability to alter APP processing. This iterative process is expected to yield several low nanomolar, lead- or drug-like selective inhibitors of BACE2. To achieve this goal, our specific aims are as follow: (1) Identify lead- and drug-like low molecular weight selective inhibitors of BACE2 using computer-aided drug design including de novo/rational drug design, virtual focused combinatorial library (vFCL) generation, and in silico screening of vFCL. To synthesize the best candidates from the de novo/rational design and vFCL approaches; (2) Assay candidate ligands for their inhibition of BACE1 and BACE2 in isolated enzyme assays. Potent, selective BACE2 inhibitors will be used for further optimization of ligand activity and selectivity through iterative molecular modeling, chemical synthesis, and biological tests; (3) For the best ligands, explore their effects on APP processing in cell-based assays. Prioritize inhibitors on the basis of activity, cytotoxicity, and resultant selectivity indices.
描述(由申请人提供):本R21探索性提案采用一种综合的、靶向的方法来合理开发BACE2抑制剂-化学工具,可用于探索BACE2的基本生物学,并提高目前发现的活性BACE1抑制剂的选择性,这些抑制剂目前正在开发作为阿尔茨海默病的药物。阿尔茨海默病研究界普遍认为,成功治疗阿尔茨海默病的关键在于特异性抑制BACE1。BACE1对于淀粉样蛋白片段的释放至关重要,这些淀粉样蛋白片段随后形成细胞外神经性淀粉样斑块,这是AD发病的一个因素。大多数已知的BACE1抑制剂是相对非选择性的,并且靶向其他天冬氨酸蛋白酶,包括高度同源的BACE2。研究表明,BACE2可能作为一种替代α -分泌酶,这是另一种在淀粉样蛋白前体蛋白(APR)降解中起重要作用的关键酶,抑制它是非常不可取的。为了更好地了解BACE2在人体生理和APP加工中的作用,我们认为需要选择这种酶的抑制剂作为研究工具。我们假设,利用基于计算机辅助药物设计、药物化学和生物学的综合多学科方法,设计和合成BACE2抑制剂应该是可能的。在低纳摩尔范围内显示BACE2活性的化合物将在全细胞水平上进行筛选,以确定其改变APP处理的能力。这一迭代过程有望产生几种低纳摩尔、铅或药物样的选择性BACE2抑制剂。为了实现这一目标,我们的具体目标如下:(1)利用计算机辅助药物设计,包括从头/合理药物设计,虚拟聚焦组合文库(vFCL)生成,以及vFCL的计算机筛选,确定BACE2的铅和药物样低分子量选择性抑制剂。从从头/理性设计和vFCL方法中综合最佳候选方案;(2)测定候选配体对分离酶BACE1和BACE2的抑制作用。有效的、选择性的BACE2抑制剂将通过反复的分子建模、化学合成和生物学测试来进一步优化配体的活性和选择性;(3)对于最佳配体,在基于细胞的检测中探索其对APP加工的影响。根据活性、细胞毒性和由此产生的选择性指数对抑制剂进行优先排序。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pavel A Petukhov其他文献
Pavel A Petukhov的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pavel A Petukhov', 18)}}的其他基金
Identification of the target of meclonazepam in schistosome worms
甲氯硝西泮在血吸虫中作用靶点的鉴定
- 批准号:
10218461 - 财政年份:2021
- 资助金额:
$ 21.14万 - 项目类别:
Identification of the target of meclonazepam in schistosome worms
甲氯硝西泮在血吸虫中作用靶点的鉴定
- 批准号:
10357874 - 财政年份:2021
- 资助金额:
$ 21.14万 - 项目类别:
Identification of preclinical drug candidates for the treatment of schistosomiasis
治疗血吸虫病的临床前候选药物的鉴定
- 批准号:
9813829 - 财政年份:2016
- 资助金额:
$ 21.14万 - 项目类别:
Small Molecule Inhibitors of Malate Synthase against M. Tuberculosis
抗结核分枝杆菌的苹果酸合酶小分子抑制剂
- 批准号:
7706254 - 财政年份:2009
- 资助金额:
$ 21.14万 - 项目类别:
Small Molecule Inhibitors of Malate Synthase against M. Tuberculosis
抗结核分枝杆菌的苹果酸合酶小分子抑制剂
- 批准号:
7897873 - 财政年份:2009
- 资助金额:
$ 21.14万 - 项目类别:
Photoaffinity labeling probes for development of novel isoform selective HDAC inh
用于开发新型亚型选择性 HDAC inh 的光亲和标记探针
- 批准号:
7525598 - 财政年份:2008
- 资助金额:
$ 21.14万 - 项目类别:
Photoaffinity labeling probes for development of novel isoform selective HDAC inh
用于开发新型亚型选择性 HDAC inh 的光亲和标记探针
- 批准号:
8067976 - 财政年份:2008
- 资助金额:
$ 21.14万 - 项目类别:
Photoaffinity labeling probes for development of novel isoform selective HDAC inh
用于开发新型亚型选择性 HDAC inh 的光亲和标记探针
- 批准号:
7841892 - 财政年份:2008
- 资助金额:
$ 21.14万 - 项目类别:
Photoaffinity labeling probes for development of novel isoform selective HDAC inh
用于开发新型亚型选择性 HDAC inh 的光亲和标记探针
- 批准号:
7648175 - 财政年份:2008
- 资助金额:
$ 21.14万 - 项目类别:
Small molecule inhibitors pantothenate synthesis against M. tuberculosis
针对结核分枝杆菌的小分子泛酸合成抑制剂
- 批准号:
7243999 - 财政年份:2006
- 资助金额:
$ 21.14万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 21.14万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 21.14万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 21.14万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 21.14万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 21.14万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 21.14万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 21.14万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 21.14万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 21.14万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 21.14万 - 项目类别:














{{item.name}}会员




